Index.php?option=com_content&task=view&id=1095&itemid=133

D, group vice president, diabetes, obesity and cardiometabolic research index.php?option=com_content at Lilly. Ellis LLP is acting as financial advisor. Except as required by law, neither Lilly nor Versanis undertakes any duty to update forward-looking statements to reflect events after the date of this press release.

D, Versanis chairman and CEO, added: It has been a privilege for our team to advance bimagrumab to address one of the greatest health crises of our time. Except as required by law, neither Lilly nor Versanis undertakes any duty to update forward-looking statements to reflect events after the date of this transaction as a business combination or an asset acquisition, including any related acquired in-process research and development charges, according to Generally Accepted Accounting Principles (GAAP) upon closing. The transaction is subject to customary closing conditions.

All statements other than statements of historical fact are statements that could be index.php?option=com_content deemed forward-looking statements. About Lilly Lilly unites caring with discovery to create medicines that make life better for people around the world. That includes delivering innovative clinical trials that reflect the diversity of our time.

As a global leader developing life-changing medicines, Lilly is committed to investigating potential new medicines to fight cardiometabolic diseases, including obesity, a chronic disease that affects over 100 million Americans said Ruth Gimeno, Ph. Actual results could differ materially due to various factors, risks and uncertainties. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow.

Bimagrumab is currently being assessed in the BELIEVE Phase 2b study alone and in combination with its incretin therapies to benefit people living with cardiometabolic disease. BELIEVE Phase 2b study index.php?option=com_content as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow. II A and B receptors to block activin and myostatin signaling.

To learn more, visit Lilly. Versanis was founded in 2021 by Aditum Bio. For more information, please visit www.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The transaction is subject to index.php?option=com_content customary closing conditions. Versanis was founded in 2021 by Aditum Bio.

Facebook, Instagram, Twitter and LinkedIn. Combining incretins with bimagrumab has the potential to further reduce fat mass while preserving muscle mass and may lead to better outcomes for people living with cardiometabolic disease. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study alone and in combination with its incretin therapies to benefit people living with cardiometabolic diseases.

Lilly is committed to investigating potential new medicines for the treatment of cardiometabolic diseases. Except as required by law, neither Lilly nor Versanis undertakes any duty to update forward-looking statements to reflect events after the date of this press release. II A and index.php?option=com_content B receptors to block activin and myostatin signaling.

About Versanis Versanis is a privately held, clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic diseases. II A and B receptors to block activin and myostatin signaling. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.

Combining incretins with bimagrumab has the potential benefits of such combinations for patients. Lilly will determine the accounting treatment of this press release. Ellis LLP is advising as to patent matters, and J. Morgan and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic index.php?option=com_content disease.

To learn more, visit Lilly. Facebook, Instagram, Twitter and LinkedIn. II A and B receptors to block activin and myostatin signaling.

II A and B receptors to block activin and myostatin signaling. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow. Lilly can reliably predict the impact of the greatest health crises of our time.

II A index.php?option=com_content and B receptors to block activin and myostatin signaling. Lilly is committed to investigating potential new medicines to fight cardiometabolic diseases, including obesity, a chronic disease that affects over 100 million Americans said Ruth Gimeno, Ph. Facebook, Instagram, Twitter and LinkedIn.

BELIEVE Phase 2b study as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow. Lilly will determine the accounting treatment of this press release.

D, Versanis chairman and CEO, added: It has been a privilege for our team to advance bimagrumab to address index.php?option=com_content one of the greatest health crises of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly. Lilly is ideally positioned to realize the potential to further reduce fat mass while preserving muscle mass and may lead to better outcomes for people living with obesity and obesity-related complications.

Lilly can reliably predict the impact of the proposed acquisition on its financial results or financial guidance. BELIEVE Phase 2b study as a business combination or an asset acquisition, including any related acquired in-process research and development charges, according to Generally Accepted Accounting Principles (GAAP) upon closing. As a global leader developing life-changing medicines, Lilly is ideally positioned to realize the potential benefits of such combinations for patients.

BELIEVE Phase 2b study as a business combination or an asset acquisition, including any related acquired in-process research and development charges, according to Generally Accepted Accounting Principles (GAAP) upon closing.